World Journal of Vaccines

Vol.9 No.1(2019), Paper ID 89405, 21 pages

DOI:10.4236/wjv.2019.91001

 

Transgene IL-21-Engineered T Cell-Based Vaccine Potently Converts CTL Exhaustion via the Activation of the mTORC1 Pathway in Chronic Infection

 

Aizhang Xu, Xueying Zhang, Rajni Chibbar, Andrew Freywald, Suresh Tikoo, Changyu Zheng, Jim Xiang

 

Cancer Research, Saskatchewan Cancer Agency, Saskatoon, Canada
Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
School of Public Health, University of Saskatchewan, Saskatoon, Canada
Molecular Physiology and Therapeutic Branch, National Institute of Dental and Craniofacial Research, National Institute of Health, Bethesda, USA
Cancer Research, Saskatchewan Cancer Agency, Saskatoon, Canada

 

Copyright © 2019 Aizhang Xu, Xueying Zhang, Rajni Chibbar, Andrew Freywald, Suresh Tikoo, Changyu Zheng, Jim Xiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


Xu, A. , Zhang, X. , Chibbar, R. , Freywald, A. , Tikoo, S. , Zheng, C. and Xiang, J. (2019) Transgene IL-21-Engineered T Cell-Based Vaccine Potently Converts CTL Exhaustion via the Activation of the mTORC1 Pathway in Chronic Infection. World Journal of Vaccines, 9, 1-21. doi: 10.4236/wjv.2019.91001.

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.